Cost Analysis of a Fracture Liaison Service: A Randomized Controlled Trial for the Secondary Prevention After Fragility Fractures of the Hip
Authors' conclusion
The present analysis shows that medication cost is the critical component in cost-effectiveness of an FLS program. The FLS program costs would be significantly lower if patients are prescribed less expensive drugs to treat osteoporosis. Additional work needs to be performed refining the medication algorithm considering medication costs but individualized to patient needs based on fracture risk.
Study context
- Population
- Patients with hip fragility fractures180 analysed for costs
- Participants
- 200 patients
- Comparison
- FLS program; cost vs savings from reduced secondary fractures
Methodological detailshospital-based
- Hospital-based
Primary result
As reported in the abstract
Overall cost per patient, study medication algorithm
$1189
Overall cost per patient if IV zoledronic acid used
$489
Overall cost per patient if only oral bisphosphonates used
$159
Medication share of costs; main factor for FLS costs exceeding savings
89%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →